Moderna’s chief executive officer doesn’t expect any problems with the development of a booster shot against the latest strain of the CCP virus and hopes clinical trials can begin early next year. “It only needs minor adjustments for Omicron. I don’t expect any problems,” Stéphane Bancel told Swiss newspaper Tages-Anzeiger, likely referring to the company’s…